The market may be falling today but that hasn't stopped one ASX All Ords stock from storming higher.
In morning trade, AVITA Medical Inc (ASX: AVH) shares are up 11% to $1.49 after it made a big announcement.
Image source: Getty Images
Why is this ASX All Ords stock storming higher?
Investors have the regenerative medicine company's shares higher today after it revealed that it has received the CE Mark under the European Union's Medical Device Regulation for its RECELL GO device.
This means AVITA can now begin commercialising the product across Europe and in other markets that recognise the certification.
AVITA Medical's chief executive, Jim Corbett, was very pleased with the news and said the approval marked a turning point for the business. He commented:
CE Mark for RECELL GO is an important milestone for AVITA Medical and for patients. It enables us to bring this option to burn centers and clinicians in Europe to support their treatment of patients with acute wound injuries.
What does AVITA Medical do?
AVITA Medical is focused on therapeutic acute wound care. Its flagship product, the RECELL System, is designed to help heal burns and traumatic wounds by using a patient's own skin.
Its technology works by creating a suspension of skin cells, which are known as Spray-On Skin Cells, which can then be applied to damaged areas to speed up recovery.
The aforementioned RECELL GO product builds on this platform by making the process simpler and more efficient at the point of care. For doctors and nurses, that means faster preparation of the cell suspension, while for patients, it can mean shorter hospital stays and improved healing outcomes. Win-win!
The ASX All Ords stock also holds exclusive rights in the U.S. to distribute complementary wound care technologies such as PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix. Together, these products give AVITA a growing portfolio of solutions aimed at improving recovery and outcomes for patients with serious wounds.
Clinical backing
Today's release also highlights that evidence presented at the 2025 European Burns Association Congress demonstrated that patients treated with RECELL experienced a 36% reduction in hospital stays compared to traditional grafting.
For health systems, that translates into lower costs. For patients, it means less time in hospital and a quicker recovery.
With the CE Mark approval, in collaboration with burn centers and clinical partners, AVITA will now begin rolling out RECELL GO in key European countries including Germany, Italy, and the UK.
